Compare · ACOR vs RVMD
ACOR vs RVMD
Side-by-side comparison of Acorda Therapeutics Inc. (ACOR) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACOR and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD carries a market cap of $37.27B.
- RVMD has hit the wire 9 times in the past 4 weeks while ACOR has been quiet.
- RVMD has more recent analyst coverage (25 ratings vs 0 for ACOR).
- Company
- Acorda Therapeutics Inc.
- Revolution Medicines Inc.
- Price
- -
- -
- Market cap
- -
- $37.27B
- 1M return
- -
- -8.97%
- 1Y return
- -
- +149.19%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2006
- 2020
- News (4w)
- 0
- 9
- Recent ratings
- 0
- 25
Acorda Therapeutics Inc.
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Selincro for the treatment of alcohol dependence; and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest ACOR
- Flow Sciences Appoints Michael Gesser as Chief Financial Officer
- SEC Form 10-Q filed by Acorda Therapeutics Inc.
- SEC Form 10-K/A filed by Acorda Therapeutics Inc. (Amendment)
- Acorda Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Acorda Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Acorda Therapeutics Reports Delisting From Nasdaq
- Acorda Therapeutics Announces Delisting from Nasdaq
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- 12 Health Care Stocks Moving In Thursday's Intraday Session
Latest RVMD
- Director Borisy Alexis gifted 10,625 shares, decreasing direct ownership by 0.45% to 2,329,450 units (SEC Form 4)
- Chief Financial Officer Anders Jack exercised 35,750 shares at a strike of $29.19 and sold $6,724,688 worth of shares (35,750 units at $188.10) as part of a pre-agreed trading plan (SEC Form 4)
- Officer Mancini Anthony exercised 811 shares at a strike of $33.70 and sold $162,200 worth of shares (811 units at $200.00) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- SEC Form 10-Q filed by Revolution Medicines Inc.
- Revolution Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
- Officer Mancini Anthony sold $431,947 worth of shares (2,310 units at $186.99) as part of a pre-agreed trading plan (SEC Form 4)
- Revolution Medicines to Participate in November 2026 Investor Conferences
- Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026